However, due to the persistence of leukemic stem cells (LSCs) independent of BCR-ABL, CML relapses occur in ∼61% of patients after TKI withdrawal, and few patients achieve complete molecular response (CMR)5,6. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.